新型调血脂药物的应用研究进展
Research Progress of Application of Novel Li-pid-Regulating Drugs
摘要: 血脂异常被世界医学界公认是导致动脉粥样硬化和心脑血管各种疾病的“元凶”。目前临床上的用于治疗血脂异常的药物主要包括他汀类、贝特类、烟酸类及胆汁酸螯合剂等。近年来，随着胆固醇代谢的一些新靶点的发现，也催生出很多有新作用机制的药物走向临床试验或上市，本文将介绍近年来新型调血脂药物的应用研究进展。
Abstract: Dyslipidemia is recognized by the world medical community as the “culprit” that causes atherosclerosis and various cardiovascular and cerebrovascular diseases. Current clinical drugs for the treatment of dyslipidemia include statins, fibrates, nicotinic acid, and bile acid sequestrants. In recent years, with the discovery of some new targets for cholesterol metabolism, many drugs with new mechanisms have also been developed for clinical trials or marketing. This article will introduce the recent advances in the application of novel lipid regulating drugs.
文章引用：商博, 隋常琪, 牧童, 杨慧. 新型调血脂药物的应用研究进展[J]. 药物资讯, 2018, 7(4): 74-78. https://doi.org/10.12677/PI.2018.74014

参考文献

[1] 陈伟伟, 高润霖, 刘力生. 《中国心血管病报告(2017)》概要[J]. 中国循环杂志, 2018, 33(1): 1-8.
[2] 国家卫生和计划生育委员会. 中国卫生和计划生育统计年鉴2016 [M]. 北京: 中国协和医科大学出版社, 2016.
[3] 中华人民共和国卫生部. 中国卫生统计年鉴2009~2012 [M]. 北京: 中国协和医科大学出版社, 2009-2012.
[4] Colin, B., Landray, M.J., Christina, R., et al. (2011) The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease (Study of Heart and Renal Protection): A Randomised Placebo-Controlled Trial. Lancet, 377, 2181-2192. [Google Scholar] [CrossRef] 
[5] Seidah, N.G., Benjannet, S., Wickham, L., et al. (2003) The Secretory Pro-protein Convertase Neural Apoptosis-Regulated Convertase 1 (NARC-1): Liver Regeneration and Neuronal Differentiation. Proceed-ings of the National Academy of Sciences of the United States of America, 100, 928-933. [Google Scholar] [CrossRef] [PubMed]
[6] Stein, E.A., Mellis, S., Yancopoulos, G.D., et al. (2012) Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. The New England Journal of Medicine, 366, 1108-1118. [Google Scholar] [CrossRef] 
[7] Koren, M.J., Scot,t R., Kim, J.B., et al. (2012) Efficacy, Safety, and Tolerability of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 as Monotherapy in Patients with Hypercholesterolaemia (MENDEL): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study. Lancet, 380, 1995-2006. [Google Scholar] [CrossRef] 
[8] Giugliano, R.P., Desai, N.R., Kohli, P., et al. (2012) Efficacy, Safety, and Tolerability of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 in Combination with a Statin in Patients with Hypercholesterolaemia (LAPLACE-TIMI 57): A Randomised, Placebo-Controlled, Dose-Ranging, Phase 2 Study. Lancet, 380, 2007-2017. [Google Scholar] [CrossRef] 
[9] Wu, Q., Tang, Z.H., Peng, J., et al. (2014) The Dual Behavior of PCSK9 in the Regulation of Apoptosis Is Crucial in Alzheimer’s Disease Progression (Review). Biomedical Reports, 2, 167-171. [Google Scholar] [CrossRef] [PubMed]
[10] Mbikay, M., Sirois, F., Mayne, J., et al. (2010) PCSK9-Deficient Mice Exhibit Impaired Glucose Tolerance and Pancreatic Islet Abnormalities. FEBS Letters, 584, 701-706. [Google Scholar] [CrossRef] [PubMed]
[11] GouniBerthold, I. and Berthold, H.K. (2015) Mipomersen and Lomitapide: Two New Drugs for the Treatment of Homozygous Familial Hypercholesterolemia. Atherosclerosis Supplements, 18, 28-34. [Google Scholar] [CrossRef] [PubMed]
[12] Cuchel, M. and Rader, D.J. (2013) Microsomal Transfer Protein Inhibition in Humans. Current Opinion in Lipidology, 24, 246-250. [Google Scholar] [CrossRef] 
[13] Wetterau, J.R., Gregg, R.E., Harrity, T.W., et al. (1998) An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits. Science, 282, 751-754. [Google Scholar] [CrossRef] [PubMed]
[14] Cuchel, M., Bloedon, L.T., Szapary, P.O., et al. (2007) Inhibition of Micro-somal Triglyceride Transfer Protein in Familial Hypercholesterolemia. The New England Journal of Medicine, 356, 148-156. [Google Scholar] [CrossRef] 
[15] Samaha, F.F., McKenney, J., Bloedon, L.T., et al. (2008) Inhibition of Microsomal Triglyceride Transfer Protein Alone or with Ezetimibe in Patients with Moderate Hypercholesterolemia. Nature Clinical Practice Car-diovascular Medicine, 5, 497-505. [Google Scholar] [CrossRef] [PubMed]
[16] Harris, W.S., Miller, M., Tighe, A.P., et al. (2008) Omega-3 Fatty Acids and Coronary Heart Disease Risk: Clinical and Mechanistic Perspectives. Atherosclerosis, 197, 12-24. [Google Scholar] [CrossRef] [PubMed]
[17] Davidson, M.H., Stein, E.A., Bays, H.E., et al. (2007) Efficacy and Tolerability of Adding Prescription Omega-3 Fatty Acids 4 g/d to Simvastatin 40 mg/d in Hypertriglyceridemic Patients: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study. Clinical Therapeutics, 29, 1354-1367. [Google Scholar] [CrossRef] [PubMed]
[18] Ballantyne, C.M., Bays, H.E., Kastelein, J.J., et al. (2012) Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients with Persistent High Triglycerides (from the ANCHOR Study). American Journal of Cardiology, 110, 984-992. [Google Scholar] [CrossRef] [PubMed]
[19] Robins, S.J., Collins, D., Wittes, J.T., et al. (2001) Relation of Gemfibrozil Treatment and Lipid Levels with Major Coronary Events: VA-HIT: A Randomized Controlled Trial. JAMA, 285, 1585-1591. [Google Scholar] [CrossRef] [PubMed]
[20] Barter, P.J. and Kastelein, J.J. (2006) Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease. Journal of the American College of Cardiology, 47, 492-499. [Google Scholar] [CrossRef] [PubMed]
[21] Brown, B.G., Zhao, X.Q., Chait, A., et al. (2001) Simvastatin and Niacin, Anti-oxidant Vitamins, or the Combination for the Prevention of Coronary Disease. The New England Journal of Medicine, 345, 1583-1592. [Google Scholar] [CrossRef] 
[22] Forrester, J.S. and Shah, P.K. (2006) Emerging Strategies for Increasing High-Density Lipoprotein. American Journal of Cardiology, 98, 1542-1549. [Google Scholar] [CrossRef] [PubMed]
[23] Eyvazian, V.A. and Frishman, W.H. (2017) Evacetrapib: Another CETP In-hibitor for Dyslipidemia with No Clinical Benefit. Cardiology in Review, 25, 43-52. [Google Scholar] [CrossRef] 
[24] Brinton, E.A., Kher, U., Shah, S., et al. (2015) Effects of Anacetrapib on Plasma Lipids in Specific Patient Subgroups in the Define (Determining the Efficacy and Tolerability of CETP Inhibition with Anace-trapib) Trial. Journal of Clinical Lipidology, 9, 65-71. [Google Scholar] [CrossRef] [PubMed]
[25] Hovingh, G.K., Kastelein, J.J., Van Deventer, S.J., et al. (2015) Cholesterolester Transfer Protein Inhibition by TA-8995 in Patients with Mild Dyslipidemia (TULIP): A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial. The Lancet, 386, 452-460. [Google Scholar] [CrossRef]